CIPLA.NS or CME: which is the higher-quality business?
Same dated snapshot (2026-09-01): CIPLA.NS scores —/100 vs CME 100/100 on the rule-based Berkshire checklist (unscored vs very high band). Quality grades the business only — the lower-quality name can still be the better deal at the right price.
| Snapshot | 2026-09-01 · source: yahoo | |
|---|---|---|
| CIPLA.NS (Cipla) | CME (CME Group) | |
| Market / sector | in · Pharma | us · Financials |
| Price | ₹1,407 | $280.94 |
| Quality score | —/100 | 100/100 |
| Engine signal | LONG · 90 bars · uPnL +7.7% | LONG · 24 bars · uPnL +10.0% |
| Total return | +3.1% | -8.9% |
Cite this page
Balance Labs Research Desk (2026-09-01). "CIPLA.NS or CME: which is the higher-quality business?." balancelabs.app · https://balancelabs.app/stocks/compare/cipla.ns-vs-cme/q/cipla.ns-or-cme-higher-quality · CC BY 4.0
Ask anything
30 free credits monthly · no card required · research support, not advice
← CIPLA.NS vs CME · snapshot 2026-09-01 · not investment advice